Actively Recruiting
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
Led by October 6 University · Updated on 2025-07-30
60
Participants Needed
1
Research Sites
114 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Polycystic ovary syndrome (PCOS) is an endocrine disorder that affects approximately 10-20% of women of reproductive age, Management strategies for PCOS include lifestyle modifications such as diet and physical activity that are the first-line approach to treatment; however, they are reported to be minimally effective in reducing weight or treating PCOS-related symptoms.Pharmacological options are also available; however, they are not explicitly approved for PCOS treatment as they have been primarily used to treat other conditions such as T2DM
CONDITIONS
Official Title
Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women diagnosed with PCOS according to Rotterdam 2003 criteria National Institute of Health criteria
You will not qualify if you...
- History of diabetes mellitus (Type 1 or 2)
- Liver or renal dysfunction
- Inflammatory diseases
- Autoimmune disease
- Cancer
- Acute cardiovascular event within last three months
- Known hypersensitivity or contraindications to use dipeptidyl peptidase-4 (DPP-4) inhibitors
- Eating disorders such as anorexia or bulimia
- Gastrointestinal disorders
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
October 6 university hospital
Giza, Egypt, 12585
Actively Recruiting
Research Team
A
ahmed hussein, phD
CONTACT
A
ahmed hussein
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here